Guillo Lucas, Rabaud Christian, Choy Ernest H, D'Amico Ferdinando, Danese Silvio, Ng Siew C, Peyrin-Biroulet Laurent
Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Marseille, France; Department of Gastroenterology, Inserm Nutrition-Génétique et Exposition aux Risques Environnementaux U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.
Department of Infectious Disease, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.
Clin Gastroenterol Hepatol. 2022 Mar;20(3):481-490. doi: 10.1016/j.cgh.2020.10.027. Epub 2020 Oct 17.
Herpes zoster is a painful dermatomal cutaneous eruption resulting from reactivation of the latent varicella-zoster virus. Patients with inflammatory bowel diseases have an increased risk of shingles compared with the general population and this risk can be increased with the use of immunosuppressive therapy. Live zoster vaccine and recombinant zoster vaccine have shown efficacy for the prevention of herpes zoster. The recombinant zoster vaccine seems to offer greater efficacy and long-term protection profile compared with the life zoster vaccine. However, their use in clinical practice still is unclear and updated vaccination recommendations are lacking. This review discusses the risk for shingles in patients with inflammatory bowel diseases, available vaccines, and their efficacy and safety profiles. We also provide guidance on who, when, and how to vaccinate for herpes zoster in routine clinical practice among patients with inflammatory bowel diseases.
带状疱疹是由潜伏的水痘-带状疱疹病毒再激活引起的一种疼痛性皮节性皮肤疹。与普通人群相比，炎症性肠病患者患带状疱疹的风险增加，并且使用免疫抑制疗法会使这种风险进一步增加。活带状疱疹疫苗和重组带状疱疹疫苗已显示出预防带状疱疹的功效。与活带状疱疹疫苗相比，重组带状疱疹疫苗似乎具有更高的功效和更长期的保护效果。然而，它们在临床实践中的应用仍不明确，且缺乏最新的疫苗接种建议。本综述讨论了炎症性肠病患者患带状疱疹的风险、可用疫苗及其功效和安全性。我们还提供了关于炎症性肠病患者在常规临床实践中谁、何时以及如何接种带状疱疹疫苗的指导。
